Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1995 2
1997 5
1998 1
1999 6
2000 6
2001 3
2002 8
2003 10
2004 13
2005 12
2006 16
2007 11
2008 10
2009 15
2010 24
2011 30
2012 21
2013 22
2014 16
2015 8
2016 6
2017 5
2018 3
2019 5
2020 1
2021 2
2022 7
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

239 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of pramipexole versus ropinirole in the treatment of Parkinson's disease.
Gencler OS, Oztekin N, Oztekin MF. Gencler OS, et al. Ideggyogy Sz. 2022 Jan 30;75(1-02):39-49. doi: 10.18071/isz.75.0039. Ideggyogy Sz. 2022. PMID: 35112520 Free article. Clinical Trial. English.
Dopamine agonist monotherapy and levodopa add-on therapy patients were randomized into two groups to receive either pramipexole or ropinirole. The maximum daily dosages of pramipexole and ropinirole were 4.5 mg and 24 mg respectively. ...CONCLUSION: This study suppo …
Dopamine agonist monotherapy and levodopa add-on therapy patients were randomized into two groups to receive either pramipexole or ro …
Safety and Efficacy of Dexpramipexole in Eosinophilic Asthma (EXHALE): A randomized controlled trial.
Siddiqui S, Wenzel SE, Bozik ME, Archibald DG, Dworetzky SI, Mather JL, Killingsworth R, Ghearing N, Schwartz JT, Ochkur SI, Jacobsen EA, Busse WW, Panettieri RA, Prussin C. Siddiqui S, et al. J Allergy Clin Immunol. 2023 Nov;152(5):1121-1130.e10. doi: 10.1016/j.jaci.2023.05.014. Epub 2023 Jun 3. J Allergy Clin Immunol. 2023. PMID: 37277072 Free article. Clinical Trial.
Add-On Pramipexole for the Treatment of Schizophrenia and Schizoaffective Disorder: A Randomized Controlled Trial.
Levi L, Zamora D, Nastas I, Gonen I, Radu P, Matei V, Ciobanu AM, Nacu A, Boronin L, Karakrah L, Davidson M, Davis JM, Weiser M. Levi L, et al. J Clin Psychiatry. 2022 Aug 1;83(5):21m14233. doi: 10.4088/JCP.21m14233. J Clin Psychiatry. 2022. PMID: 35921506 Clinical Trial.
Objective: Several small clinical trials have reported that the dopamine agonist pramipexole was beneficial in treating patients with schizophrenia. ...Changes in Clinical Global Impressions-Severity of Illness scale and Brief Assessment of Cognition in Schizophrenia score …
Objective: Several small clinical trials have reported that the dopamine agonist pramipexole was beneficial in treating patients with …
Comparative Pharmacokinetics and Bioequivalence Evaluation of Two Formulations of Pramipexole Dihydrochloride Extended-Release Tablets in Healthy Chinese Subjects Under Fasted and Fed States: A Randomized, Open-Label, Single-Dose, Two-Period Crossover Clinical Trial.
Yang L, Zhang L, Luo Z. Yang L, et al. Drug Des Devel Ther. 2023 Aug 15;17:2369-2381. doi: 10.2147/DDDT.S421449. eCollection 2023. Drug Des Devel Ther. 2023. PMID: 37600497 Free PMC article. Clinical Trial.
BACKGROUND: Pramipexole dihydrochloride extended-release tablet is a novel long-acting form of non-ergot dopamine agonist indicated as one of main therapeutic approaches for Parkinson's disease. ...KG) formulations of pramipexole dihydrochloride extended-release tab …
BACKGROUND: Pramipexole dihydrochloride extended-release tablet is a novel long-acting form of non-ergot dopamine agonist indicated a …
A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease.
Olanow CW, Kieburtz K, Leinonen M, Elmer L, Giladi N, Hauser RA, Klepiskaya OS, Kreitzman DL, Lew MF, Russell DS, Kadosh S, Litman P, Friedman H, Linvah N, The P B Study Group F. Olanow CW, et al. Mov Disord. 2017 May;32(5):783-789. doi: 10.1002/mds.26941. Epub 2017 Apr 3. Mov Disord. 2017. PMID: 28370340 Clinical Trial.
BACKGROUND: Rasagiline and pramipexole act to improve striatal dopaminergic transmission in PD via distinct and potentially synergistic mechanisms. ...METHODS: Previously untreated patients with early PD were randomized (1:1:1) to once-daily treatment with P2B001 (0.3 mg …
BACKGROUND: Rasagiline and pramipexole act to improve striatal dopaminergic transmission in PD via distinct and potentially synergist …
Comparative Analysis of the Effects of Escitalopram, Pramipexole, and Transcranial Magnetic Stimulation on Depression in Patients With Parkinson Disease: An Open-Label Randomized Controlled Trial.
Chen J, Xu P, Guo X, Zou T. Chen J, et al. Clin Neuropharmacol. 2022 Jul-Aug 01;45(4):84-88. doi: 10.1097/WNF.0000000000000507. Epub 2022 Feb 1. Clin Neuropharmacol. 2022. PMID: 35652703 Free PMC article. Clinical Trial.
There was no statistical difference between escitalopram and pramipexole, but all of them were superior to rTMS. Further logistic regression analysis suggested that 50% reduction in HAMD score from baseline was associated with the treatment method. Among them, escitalopram …
There was no statistical difference between escitalopram and pramipexole, but all of them were superior to rTMS. Further logistic reg …
A multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette's syndrome.
Kurlan R, Crespi G, Coffey B, Mueller-Vahl K, Koval S, Wunderlich G; Pramipexole for TS Trial Investigators. Kurlan R, et al. Mov Disord. 2012 May;27(6):775-8. doi: 10.1002/mds.24919. Epub 2012 Mar 7. Mov Disord. 2012. PMID: 22407510 Clinical Trial.
In patients with attention deficit hyperactivity disorder, there was improvement in DuPaul ADHD scale scores for patients receiving pramipexole compared with placebo. CONCLUSIONS: There was no evidence that pramipexole has efficacy in suppressing tics. Pramipexol
In patients with attention deficit hyperactivity disorder, there was improvement in DuPaul ADHD scale scores for patients receiving prami
Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood.
Montagna P, Hornyak M, Ulfberg J, Hong SB, Koester J, Crespi G, Albrecht S. Montagna P, et al. Sleep Med. 2011 Jan;12(1):34-40. doi: 10.1016/j.sleep.2010.08.005. Epub 2010 Oct 20. Sleep Med. 2011. PMID: 20965780 Clinical Trial.
RESULTS: The intent-to-treat population comprised 199 patients on placebo and 203 on pramipexole. At week 12, adjusted mean total-score changes on IRLS were -14.20.7 for pramipexole and -8.10.7 for placebo (p<0.0001), and on the Beck Depression Inventory version …
RESULTS: The intent-to-treat population comprised 199 patients on placebo and 203 on pramipexole. At week 12, adjusted mean total-sco …
Pramipexole to Improve Cognition in Bipolar Disorder: A Randomized Controlled Trial.
Van Meter AR, Perez-Rodriguez MM, Braga RJ, Shanahan M, Hanna L, Malhotra AK, Burdick KE. Van Meter AR, et al. J Clin Psychopharmacol. 2021 Jul-Aug 01;41(4):421-427. doi: 10.1097/JCP.0000000000001407. J Clin Psychopharmacol. 2021. PMID: 33956703 Free PMC article. Clinical Trial.
All had stable mood and clinically significant neurocognitive impairment at baseline. Participants were randomized to receive pramipexole (n = 31) or a placebo (n = 29), dose was initiated at 0.125 mg 2 times a day and increased to a target of 4.5 mg/d. ...No serious adver …
All had stable mood and clinically significant neurocognitive impairment at baseline. Participants were randomized to receive pramipexole
239 results